For GHK-Cu, the most defensible dosage discussion comes from published topical study designs and clinical-trial protocols, not from unsourced injectable peptide therapy schedules [2], [3], [7], [8]
Your doctor may recommend a GLP-1 agonist if you: Have type 2 diabetes and need better blood sugar control after meals Need to lose weight to improve your diabetes management Have cardiovascular disease or are at high risk for heart problems Have chronic kidney disease (certain GLP-1s have kidney-protective benefits) Havent reached your blood sugar targets with metformin alone Want to delay or avoid starting insulin therapy Do GLP-1 Agonists Help with Type 1 or Type 1.5 Diabetes
Archived (PDF) from the original on 14 May 2018
The phrase "NAD peptide" usually refers to injectable NAD+ rather than a true peptide compound
A 2025 systematic review by Vasireddi and colleagues in HSS Journal screened 544 published papers and identified 36 meeting inclusion criteria 35 preclinical studies and only one human study: an uncontrolled, unblinded, retrospective case series of 12 patients receiving intra-articular BPC-157 for chronic knee pain, in which 7 of 12 (58%) reported self-described relief lasting more than 6 months, with no dose, effect size, or systematically collected adverse events published
Hims & Hers' weight loss business continues to be a major focus for the company, and that segment is on pace to bring in $725 million in revenue in 2025, Yemi Okupe, Hims & Hers' chief financial officer, said during the Q3 call with investors in early November